JP2019511550A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019511550A5 JP2019511550A5 JP2018554089A JP2018554089A JP2019511550A5 JP 2019511550 A5 JP2019511550 A5 JP 2019511550A5 JP 2018554089 A JP2018554089 A JP 2018554089A JP 2018554089 A JP2018554089 A JP 2018554089A JP 2019511550 A5 JP2019511550 A5 JP 2019511550A5
- Authority
- JP
- Japan
- Prior art keywords
- hepatocellular carcinoma
- compound
- fxr agonist
- pharmaceutically acceptable
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662321816P | 2016-04-13 | 2016-04-13 | |
| US62/321,816 | 2016-04-13 | ||
| US201762468259P | 2017-03-07 | 2017-03-07 | |
| US62/468,259 | 2017-03-07 | ||
| PCT/US2017/026931 WO2017180577A1 (en) | 2016-04-13 | 2017-04-11 | Methods of treating cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019511550A JP2019511550A (ja) | 2019-04-25 |
| JP2019511550A5 true JP2019511550A5 (enExample) | 2020-03-05 |
| JP6968821B2 JP6968821B2 (ja) | 2021-11-17 |
Family
ID=60039308
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018554089A Active JP6968821B2 (ja) | 2016-04-13 | 2017-04-11 | 癌を治療する方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US10369160B2 (enExample) |
| EP (1) | EP3442946A4 (enExample) |
| JP (1) | JP6968821B2 (enExample) |
| KR (1) | KR102377338B1 (enExample) |
| CN (1) | CN109071452A (enExample) |
| AU (1) | AU2017249226B2 (enExample) |
| CA (1) | CA3020698A1 (enExample) |
| IL (1) | IL262342B (enExample) |
| TW (1) | TW201737919A (enExample) |
| WO (1) | WO2017180577A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201832768A (zh) * | 2017-03-07 | 2018-09-16 | 英特賽普醫藥品公司 | 治療癌症的方法 |
| EP3723811A4 (en) * | 2017-12-14 | 2021-09-01 | Tarveda Therapeutics, Inc. | TARGETING HSP90 CONJUGATES AND FORMULATIONS OF THE LATTER |
| CN108680696B (zh) * | 2018-05-15 | 2020-06-30 | 南京正大天晴制药有限公司 | 一种奥贝胆酸起始物料的检测方法 |
| US20230146782A1 (en) * | 2019-08-06 | 2023-05-11 | Du Jessica Xinyun | Deoxycholic acid compounds, pharmaceutical compositions and uses thereof |
| JP2022552655A (ja) | 2019-10-07 | 2022-12-19 | キャリーオペ，インク． | Ｇｐｒ１１９アゴニスト |
| MX2022010548A (es) | 2020-02-28 | 2022-09-23 | Kallyope Inc | Agonistas de gpr40. |
| MX2022014505A (es) | 2020-05-19 | 2022-12-13 | Kallyope Inc | Activadores de la ampk. |
| CA3183575A1 (en) | 2020-06-26 | 2021-12-30 | Iyassu Sebhat | Ampk activators |
| CN113143936B (zh) * | 2021-02-10 | 2022-03-25 | 北京蕴汇医药科技有限公司 | 鹅去氧胆酸或其衍生物在制备egfr和/或stat3的抑制剂中的用途 |
| CN114306349A (zh) * | 2022-01-07 | 2022-04-12 | 北京蕴汇医药科技有限公司 | 鹅去氧胆酸或其衍生物制备协同预防或治疗与egfr相关疾病药物的用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1392714T3 (da) | 2001-03-12 | 2006-01-09 | Intercept Pharmaceuticals Inc | Steroider som agonister for FXR |
| WO2003080803A2 (en) | 2002-03-21 | 2003-10-02 | Smithkline Beecham Corporation | Methods of using farnesoid x receptor (fxr) agonists |
| ITMI20050912A1 (it) | 2005-05-19 | 2006-11-20 | Erregierre Spa | Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici |
| DK2040713T3 (da) | 2006-06-27 | 2014-09-29 | Intercept Pharmaceuticals Inc | Galdesyrederivater som fxr-ligander til forebyggelsen eller behandlingen af fxr-medierede sygdomme eller tilstande |
| US8338628B2 (en) | 2007-08-28 | 2012-12-25 | City Of Hope | Method of synthesizing alkylated bile acid derivatives |
| HUE039171T2 (hu) | 2008-11-19 | 2018-12-28 | Intercept Pharmaceuticals Inc | TGR5 modulátorok és azok alkalmazási eljárása |
| WO2013037482A1 (en) * | 2011-09-15 | 2013-03-21 | Phenex Pharmaceuticals Ag | Farnesoid x receptor agonists for cancer treatment and prevention |
| NZ707389A (en) | 2012-10-26 | 2018-08-31 | Intercept Pharmaceuticals Inc | Process for preparing bile acid derivatives |
| WO2014085474A1 (en) * | 2012-11-28 | 2014-06-05 | Intercept Pharmaceuticals, Inc. | Treatment of pulmonary disease |
| US9814733B2 (en) * | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
| CN105377870B (zh) * | 2013-05-14 | 2018-04-03 | 英特塞普特医药品公司 | 作为法尼醇x受体调节剂的胆汁酸的11‑羟基衍生物及其氨基酸共轭物 |
| WO2015183794A1 (en) * | 2014-05-27 | 2015-12-03 | City Of Hope | Tgr5 agonist complexes for treating diabetes and cancer |
| PE20180690A1 (es) * | 2015-04-27 | 2018-04-23 | Intercept Pharmaceuticals Inc | Composiciones de acido obeticolico y metodos de uso |
| AU2016326428A1 (en) * | 2015-09-21 | 2018-04-12 | Intercept Pharmaceuticals, Inc. | Methods of promoting hepatic regeneration |
-
2017
- 2017-04-11 CA CA3020698A patent/CA3020698A1/en active Pending
- 2017-04-11 EP EP17782949.6A patent/EP3442946A4/en active Pending
- 2017-04-11 JP JP2018554089A patent/JP6968821B2/ja active Active
- 2017-04-11 KR KR1020187032531A patent/KR102377338B1/ko active Active
- 2017-04-11 US US15/484,379 patent/US10369160B2/en active Active
- 2017-04-11 WO PCT/US2017/026931 patent/WO2017180577A1/en not_active Ceased
- 2017-04-11 IL IL262342A patent/IL262342B/en unknown
- 2017-04-11 CN CN201780026925.5A patent/CN109071452A/zh active Pending
- 2017-04-11 AU AU2017249226A patent/AU2017249226B2/en active Active
- 2017-04-12 TW TW106112194A patent/TW201737919A/zh unknown
-
2019
- 2019-06-17 US US16/443,085 patent/US20190298742A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202092320A1 (ru) | Гетеробициклические ингибиторы mat2a и способы использования для лечения злокачественной опухоли | |
| EP3344253B1 (en) | Varlitinib for use in the treatment of resistant or refractory cancer | |
| JP2021063088A5 (enExample) | ||
| JP7367910B2 (ja) | がんの処置 | |
| AU2015394135B2 (en) | Cancer treatments | |
| BR112019024525A2 (pt) | composto, sal farmaceuticamente aceitável e formulação farmacêutica de inibidores de kras c12c | |
| JP2020515578A5 (enExample) | ||
| EA201290062A1 (ru) | Соединения, связывающие белки теплового шока, композиции и способы получения указанных соединений | |
| JP2015536964A5 (enExample) | ||
| JP2017516775A5 (enExample) | ||
| JP2015145410A5 (enExample) | ||
| JP2020502271A5 (enExample) | ||
| HUS1600021I1 (hu) | MEK inhibitorok és módszerek azok felhasználására | |
| JP2019507781A5 (enExample) | ||
| JP2018529698A5 (enExample) | ||
| CL2008000020A1 (es) | Compuestos derivados de 2,4-dianilinopirimidinas sustituidas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y tumores malignos. | |
| JP2023500483A5 (enExample) | ||
| JP2017526662A5 (enExample) | ||
| RU2016110874A (ru) | Комбинация ингибитора alk и ингибитора cdk для лечения клеточных пролиферативных заболеваний | |
| JP2017511377A5 (enExample) | ||
| RU2007145489A (ru) | Фармацевтические композиции и способы лечения рака и его метастазов | |
| JP2019519533A5 (enExample) | ||
| EA201991812A1 (ru) | Композиции и способы для визуализации и лучевой терапии рака | |
| JP2021523170A5 (enExample) | ||
| JP2019506392A5 (enExample) |